COMBINING SYNERGIES OF A BREAKTHROUGH TECHNOLOGY WITH CUTTING EDGE IMMUNOLOGICAL SCIENCE
The tremendous increase in knowledge on how the human immune system functions has enabled a revolution in cancer therapeutics through enabling a first generation of immune check point blockades. Considered one of the most promising approaches, immune-oncology based therapeutic strategies are aimed at reactivating natural immune defenses against tumors.
In following this new scientific direction to establish its proprietary or collaborative pipeline of cancer therapeutics, H-Immune deploys its proprietary Ab technology against novel waves of immune modulating targets that are known to play key roles in cancer immune escape mechanisms.
This innovative approach represents a new paradigm for development of cancer cures, a profound contrast to the former gold standard of chemotherapeutic-based medicines.